1h Free Analyst Time
The publisher has been monitoring the hepatic encephalopathy (HE) therapeutics market and it is poised to grow by $1 bn during 2021-2025, progressing at a CAGR of 6.08% during the forecast period. The report on the hepatic encephalopathy (HE) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the availability of patient-focused programs to assist disease management and the availability of co-pay assistance programs.
The hepatic encephalopathy (HE) therapeutics market analysis includes the product segment and geographic landscape.
The hepatic encephalopathy (HE) therapeutics market is segmented as below:
By Product
- NADs
- Antibiotics
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the high unmet needs as one of the prime reasons driving the hepatic encephalopathy (HE) therapeutics market growth during the next few years.
The report on hepatic encephalopathy (HE) therapeutics market covers the following areas:
- Hepatic encephalopathy (HE) therapeutics market sizing
- Hepatic encephalopathy (HE) therapeutics market forecast
- Hepatic encephalopathy (HE) therapeutics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hepatic encephalopathy (HE) therapeutics market vendors that include Alfasigma Spa, ASKA Pharmaceutical Co. Ltd., Bausch Health Companies Inc., COSMO PHARMACEUTICALS NV, Cumberland Pharmaceuticals Inc., Horizon Therapeutics Plc, Lupin Ltd., Mallinckrodt Plc, Norgine BV, and Rebiotix Inc. Also, the hepatic encephalopathy (HE) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product
- NADs - Market size and forecast 2020-2025
- Antibiotics - Market size and forecast 2020-2025
- Others - Market size and forecast 2020-2025
- Market opportunity by Product
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Alfasigma Spa
- ASKA Pharmaceutical Co. Ltd.
- Bausch Health Companies Inc.
- COSMO PHARMACEUTICALS NV
- Cumberland Pharmaceuticals Inc.
- Horizon Therapeutics Plc
- Lupin Ltd.
- Mallinckrodt Plc
- Norgine BV
- Rebiotix Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2020 - 2025 ($ million)
- Global market: Year-over-year growth 2020 - 2025 (%)
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2020
- Product - Market share 2020-2025 (%)
- Comparison by Product
- NADs - Market size and forecast 2020-2025 ($ million)
- NADs - Year-over-year growth 2020-2025 (%)
- Antibiotics - Market size and forecast 2020-2025 ($ million)
- Antibiotics - Year-over-year growth 2020-2025 (%)
- Others - Market size and forecast 2020-2025 ($ million)
- Others - Year-over-year growth 2020-2025 (%)
- Market opportunity by Product
- Customer landscape
- Market share By Geographical Landscape 2020-2025 (%)
- Geographic comparison
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Asia - Market size and forecast 2020-2025 ($ million)
- Asia - Year-over-year growth 2020-2025 (%)
- ROW - Market size and forecast 2020-2025 ($ million)
- ROW - Year-over-year growth 2020-2025 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Alfasigma Spa - Overview
- Alfasigma Spa - Product and service
- Alfasigma Spa - Key offerings
- Alfasigma Spa - Key customers
- Alfasigma Spa - Segment focus
- ASKA Pharmaceutical Co. Ltd. - Overview
- ASKA Pharmaceutical Co. Ltd. - Business segments
- ASKA Pharmaceutical Co. Ltd. - Key offerings
- ASKA Pharmaceutical Co. Ltd. - Key customers
- ASKA Pharmaceutical Co. Ltd. - Segment focus
- Bausch Health Companies Inc. - Overview
- Bausch Health Companies Inc. - Business segments
- Bausch Health Companies Inc. - Key offerings
- Bausch Health Companies Inc. - Key customers
- Bausch Health Companies Inc. - Segment focus
- COSMO PHARMACEUTICALS NV - Overview
- COSMO PHARMACEUTICALS NV - Business segments
- COSMO PHARMACEUTICALS NV - Key offerings
- COSMO PHARMACEUTICALS NV - Key customers
- COSMO PHARMACEUTICALS NV - Segment focus
- Cumberland Pharmaceuticals Inc. - Overview
- Cumberland Pharmaceuticals Inc. - Business segments
- Cumberland Pharmaceuticals Inc. - Key offerings
- Cumberland Pharmaceuticals Inc. - Key customers
- Cumberland Pharmaceuticals Inc. - Segment focus
- Horizon Therapeutics Plc - Overview
- Horizon Therapeutics Plc - Business segments
- Horizon Therapeutics Plc - Key offerings
- Horizon Therapeutics Plc - Key customers
- Horizon Therapeutics Plc - Segment focus
- Lupin Ltd. - Overview
- Lupin Ltd. - Product and service
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Key customers
- Lupin Ltd. - Segment focus
- Mallinckrodt Plc - Overview
- Mallinckrodt Plc - Business segments
- Mallinckrodt Plc - Key offerings
- Mallinckrodt Plc - Key customers
- Mallinckrodt Plc - Segment focus
- Norgine BV - Overview
- Norgine BV - Product and service
- Norgine BV - Key offerings
- Norgine BV - Key customers
- Norgine BV - Segment focus
- Rebiotix Inc. - Overview
- Rebiotix Inc. - Product and service
- Rebiotix Inc. - Key offerings
- Rebiotix Inc. - Key customers
- Rebiotix Inc. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global hepatic encephalopathy (he) therapeutics market: Alfasigma Spa, ASKA Pharmaceutical Co. Ltd., Bausch Health Companies Inc., COSMO PHARMACEUTICALS NV, Cumberland Pharmaceuticals Inc., Horizon Therapeutics Plc, Lupin Ltd., Mallinckrodt Plc, Norgine BV, and Rebiotix Inc.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is high unmet needs.`
According to the report, one of the major drivers for this market is the availability of patient-focused programs to assist disease management.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alfasigma Spa
- ASKA Pharmaceutical Co. Ltd.
- Bausch Health Companies Inc.
- COSMO PHARMACEUTICALS NV
- Cumberland Pharmaceuticals Inc.
- Horizon Therapeutics Plc
- Lupin Ltd.
- Mallinckrodt Plc
- Norgine BV
- Rebiotix Inc.
